Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Head & Neck 1Gynecologic 1Endocrine 1Breast 1

Conditions

Ovarian Neoplasms 40Breast Neoplasms 14Uterine Cervical Neoplasms 13Melanoma 13Carcinoma, Non-Small-Cell Lung 13Pancreatic Neoplasms 11Colorectal Neoplasms 10Neoplasm Metastasis 8Head and Neck Neoplasms 8Stomach Neoplasms 7Triple Negative Breast Neoplasms 6Fallopian Tube Neoplasms 6Esophageal Neoplasms 6Anus Neoplasms 6Vaginal Neoplasms 5Penile Neoplasms 5Lung Neoplasms 5Carcinoma, Ovarian Epithelial 5Carcinoma, Hepatocellular 5Vulvar Neoplasms 4Urogenital Neoplasms 4Urinary Bladder Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Sarcoma, Synovial 4Oropharyngeal Neoplasms 4Neoplasms 4Multiple Myeloma 4Mesothelioma 4Carcinoma, Renal Cell 4Recurrence 3

Interventions

aldesleukin 2Trastuzumab 2zimberelimab 1trametinib 1tipifarnib 1sargramostim 1fludarabine 1dabrafenib 1cobimetinib 1Vemurafenib 1Nivolumab 1Ipilimumab 1Interleukin-12 Subunit p35 1Interleukin-12 1Cyclophosphamide 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Thyroid Carcinoma, Anaplastic × fludarabine × Gynecologic × Clear all
NCT03449108 2026-05-22

LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
30 enrolled
BreastEndocrineGynecologicHead & NeckSarcoma

Bone Neoplasms, Ovarian Neoplasms, Sarcoma, Osteosarcoma, Giant Cell Tumor of Bone, Histiocytoma, Malignant Fibrous, Triple Negative Breast Neoplasms, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡